Premium
Hyperparathyroidism Associated with Long‐Term Proton Pump Inhibitors Independent of Concurrent Bisphosphonate Therapy in Elderly Adults
Author(s) -
Hinson Andrew M.,
Wilkerson Bekka M.,
RothmanFitts Ivy,
Riggs Ann T.,
Stack Brendan C.,
Bodenner Donald L.
Publication year - 2015
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/jgs.13661
Subject(s) - medicine , creatinine , vitamin d and neurology , parathyroid hormone , hyperparathyroidism , renal function , endocrinology , vitamin d deficiency , calcium , gastroenterology , secondary hyperparathyroidism , urology
Objectives To measure the effect of proton pump inhibitors ( PPI s), with and without concurrent bisphosphonates, on parathyroid hormone ( PTH ), vitamin D, and calcium. Design Retrospective chart review of individuals 60 years and older. Subjects with reduced renal function (creatinine >1.3 mg/ dL ) and low vitamin D (<30 ng/ mL ) were excluded. Setting Academic geriatric outpatient center in southern midwest. Participants Individuals aged 60 and older with concurrent calcium, PTH , vitamin D, and creatinine laboratory measurements ( N = 80) meeting labeled criteria. Measurements Serum calcium, PTH , vitamin D, and creatinine. Results Chronic PPI exposure was associated with statistically significantly higher PTH (65.5 vs 30.3 pg/ mL , P < .001; normal range 10–55 pg/ mL ) and lower calcium (9.1 vs 9.4 mg/ dL , P = .02; normal range 8.5–10.5 mg/ dL ) than no PPI exposure. Chronic PPI exposure with concurrent BP therapy was associated with statistically significantly higher PTH (65.2 vs 43.4 pg/ mL , P = .05) and lower calcium (9.2 vs 9.6 mg/ dL , P = .04) than BP therapy only. Conclusion Based on the present study, chronic PPI exposure in elderly adults is associated with mild hyperparathyroidism regardless of concurrent oral BP administration.